Akademik Veri Yönetim Sistemi
EPIGENOMICS, ss.1-20, 2026 (SCI-Expanded, Scopus)
Breast cancer represents a molecularly heterogeneous disease shaped by complex genetic, epigenetic,and transcriptional dysregulation. Non-coding RNAs (ncRNAs) including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) as well as small nucleolar RNAs (snoRNAs), piwi-interacting RNAs (piRNAs), and small nuclear RNAs (snRNAs), have emerged as key epigenetic regulatorsthat integrate multiple layers of gene control. Through interactions with chromatin-modifying enzymes,RNA-binding proteins, and signaling effectors, ncRNAs modulate transcriptional activity, chromatinaccessibility, and post-transcriptional stability of target genes. miRNAs predominantly act as post-transcriptional repressors, whereas lncRNAs and circRNAs exert transcriptional and epigenetic controlvia scaffolding, miRNA sponging, and chromatin remodeling; some circRNAs even encode functionalpeptides. Aberrant ncRNA expression contributes to proliferation, metastasis, metabolic reprogram-ming, immune evasion, and therapeutic resistance, with distinct expression signatures associated withtriple-negative, HER2-positive, and hormone receptor – positive breast cancers. Owing to their stabilityand detectability in plasma and exosomes, ncRNAs hold promise as minimally invasive biomarkers forearly detection and disease monitoring. Moreover, therapeutic strategies targeting ncRNAs, such asantisense oligonucleotides, RNA interference, CRISPR/Cas-based editing, and ncRNA-derived vaccines,are advancing toward clinical translation. Collectively, ncRNAs redefine the epigenetic landscape ofbreast cancer, offering a framework for integrated diagnostic and therapeutic approaches in precisiononcology.